Call for Expressions of Interest (EoI)
Over the past nine years ACH2 has supported translational research in the areas of human immunodeficiency virus (HIV), hepatitis C virus (HCV) and more recently hepatitis B virus (HBV). In 2016 - 2017, ACH2 will continue to support translational research into these three viruses.
ACH2 is seeking expressions of interest (EoI) in applied research from qualified scientists to fund research projects aimed at: i) developing vaccine candidates, antiviral drug strategies, novel diagnostics and prognostics for HIV, HBV, HCV or hepatitis B/C/HIV co-infection; ii) molecular tools for tracking epidemics caused by these organisms; and iii) new tests for supporting vaccine and antiviral trials. Basic research grants are not sought. Grants based on the specimens obtained from the Immunovirology Research Network collected from clinical trials or cohort studies of patients with HIV, HBV or HCV are also encouraged.
These grants are intended to complement and translate basic research in the virology and immunology of HIV, HBV and HCV usually initially funded by other granting bodies.
Funding is available from 1 July 2016 to 30 June 2017 for grants up to $100,000.
One EoI per chief investigator (CI)-A will be considered.
Eligibility: CIs must be equivalent to NHMRC PSP 4, usually with independent funding.
ACH2 grants will be awarded to the administering organization through which the CIA submits their application. All awards will be governed by a participant agreement (between the participant organization and The Westmead Institute for Medical Research representing ACH2). All administering organisations awarded a grant will be required to enter such an agreement.
A pamphlet explaining the details and eligibility criteria of this funding is available at www.ach2.org.au/apply or:
Executive Officer, ACH2
The Westmead Institute for Medical Research
PO Box 412
Westmead NSW 2145
Phone: (02) 8627 3004
Fax: (02) 8627 3099
Expressions of Interest close at 5:00 p.m. AEDT on Wednesday, 29 June, 2016.